450 related articles for article (PubMed ID: 8630957)
61. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody.
Lacroix-Triki M; Mery E; Voigt JJ; Istier L; Rochaix P
Virchows Arch; 2003 Jun; 442(6):548-54. PubMed ID: 12712335
[TBL] [Abstract][Full Text] [Related]
62. MIB-1 Proliferation Index in Ductal Carcinoma In Situ of the Breast: Relationship to the Expression of the Apoptosis-Regulating Proteins bcl-2 and p53.
Siziopikou KP; Schnitt SJ
Breast J; 2000 Nov; 6(6):400-406. PubMed ID: 11348399
[TBL] [Abstract][Full Text] [Related]
63. Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast.
Afify A; McNiel MA; Braggin J; Bailey H; Paulino AF
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):121-7. PubMed ID: 18227732
[TBL] [Abstract][Full Text] [Related]
64. p53 protein expression in ductal carcinoma in situ (DCIS) of the breast.
Rajan PB; Scott DJ; Perry RH; Griffith CD
Breast Cancer Res Treat; 1997 Feb; 42(3):283-90. PubMed ID: 9065612
[TBL] [Abstract][Full Text] [Related]
65. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Sasano H
Jpn J Cancer Res; 2000 Nov; 91(11):1169-76. PubMed ID: 11092983
[TBL] [Abstract][Full Text] [Related]
66. Immunohistochemical categorisation of ductal carcinoma in situ of the breast.
Meijnen P; Peterse JL; Antonini N; Rutgers EJ; van de Vijver MJ
Br J Cancer; 2008 Jan; 98(1):137-42. PubMed ID: 18043578
[TBL] [Abstract][Full Text] [Related]
67. Immunohistochemical study of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinase 1 in benign and malignant breast tissue--strong expression in intraductal carcinomas of the breast.
Rahko E; Kauppila S; Pääkkö P; Blanco G; Apaja-Sarkkinen M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Jukkola A
Tumour Biol; 2009; 30(5-6):257-64. PubMed ID: 19887890
[TBL] [Abstract][Full Text] [Related]
68. [Role of cytokeratin expression in differential diagnosis of intraductal proliferative lesions of breast].
Zhang JL; Zhang HY; Wei B; Lang ZQ; Bu H
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):316-9. PubMed ID: 15363314
[TBL] [Abstract][Full Text] [Related]
69. Expression of proteoglycan versican in in situ breast lesions: relations between stromal changes, histotype, and invasion.
Canavese G; Candelaresi G; Castellano I; Mano MP
Pathol Res Pract; 2011 Feb; 207(2):97-103. PubMed ID: 21185131
[TBL] [Abstract][Full Text] [Related]
70. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
71. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
72. Protein kinase C alpha expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma.
Ainsworth PD; Winstanley JH; Pearson JM; Bishop HM; Garrod DR
Eur J Cancer; 2004 Oct; 40(15):2269-73. PubMed ID: 15454252
[TBL] [Abstract][Full Text] [Related]
73. Expression of survivin, bcl-2, P53 and bax in breast carcinoma and ductal intraepithelial neoplasia (DIN 1a).
Kayaselcuk F; Nursal TZ; Polat A; Noyan T; Yildirim S; Tarim A; Seydaoglu G
J Exp Clin Cancer Res; 2004 Mar; 23(1):105-12. PubMed ID: 15149158
[TBL] [Abstract][Full Text] [Related]
74. Incidental atypical proliferative lesions in reduction mammoplasty specimens in patients with a history of breast cancer.
Li Z; Fadare O; Hameed O; Zhao C; Desouki MM
Hum Pathol; 2014 Jan; 45(1):104-9. PubMed ID: 24182561
[TBL] [Abstract][Full Text] [Related]
75. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family.
Abdel-Fatah TM; Powe DG; Hodi Z; Reis-Filho JS; Lee AH; Ellis IO
Am J Surg Pathol; 2008 Apr; 32(4):513-23. PubMed ID: 18223478
[TBL] [Abstract][Full Text] [Related]
76. [Expression of glucose transporter 1 in human breast carcinoma and its clinical significance].
Hao LS; Ni Q; Jia GQ; Wang G; Qian K; Liu YJ; Zhang Y; Wu XT
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):44-7. PubMed ID: 19292042
[TBL] [Abstract][Full Text] [Related]
77. Cyclin D1 expression in ductal carcinoma in situ, atypical ductal hyperplasia and usual ductal hyperplasia: an immunohistochemical study.
Umekita Y; Yoshida H
Pathol Int; 2000 Jul; 50(7):527-30. PubMed ID: 10886733
[TBL] [Abstract][Full Text] [Related]
78. Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ.
Tozbikian G; Brogi E; Vallejo CE; Giri D; Murray M; Catalano J; Olcese C; Van Zee KJ; Wen HY
Int J Surg Pathol; 2017 Apr; 25(2):100-107. PubMed ID: 27481892
[TBL] [Abstract][Full Text] [Related]
79. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast.
Buerger H; Simon R; Schäfer KL; Diallo R; Littmann R; Poremba C; van Diest PJ; Dockhorn-Dworniczak B; Böcker W
Mol Pathol; 2000 Jun; 53(3):118-21. PubMed ID: 10897329
[TBL] [Abstract][Full Text] [Related]
80. Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas.
Kapucuoglu N; Losi L; Eusebi V
Virchows Arch; 1997 Jan; 430(1):17-22. PubMed ID: 9037310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
